Stock listing

NASDAQ:SBFM Sunshine Biopharma Inc. Stock

Home listing (NASDAQ) of Sunshine Biopharma Inc.

Follow Sunshine Biopharma Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:SBFM

$2.23 USD -0.18 (-7.5%)

Close on Nov 20, 2026

Past year -99.2% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$2.23 – $2.35 USDNov 20, 2026
Volume
22,863 sharesNov 20, 2026
Market cap
$1.84M USDAt the close on Nov 20, 2026 · price × 823,772 shares outstanding
52-week range
$2.23 – $464.00 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$248,758 USDMedian day 2,548 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Sunshine Biopharma Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:SBFM · Home$2.23 USD-0.18 (-7.5%)22,863$2.32$2.35$2.23$2.41Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:SBFM · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$2.23-0.18-7.5%$2.32$2.35$2.2322,863
$2.41-0.13-5.1%$2.52$2.52$2.4116,230
$2.54-0.06-2.3%$2.59$2.59$2.5125,880
$2.60-0.10-3.7%$2.61$2.68$2.5536,863
$2.70-0.14-4.9%$2.72$2.775$2.7027,454
$2.84+0.09+3.3%$2.70$2.95$2.6948,819
$2.75-0.10-3.5%$2.78$2.82$2.70945,498
$2.85+0.10+3.6%$2.75$2.85$2.6940,092
$2.75+0.04+1.5%$2.76$2.82$2.7017,094
$2.71-0.08-2.9%$2.73$2.85$2.6835,947
$2.79+0.14+5.3%$2.69$2.91$2.5370,609
$2.65-0.09-3.3%$2.77$2.82$2.60188,011
$2.74-0.01-0.4%$2.70$2.87$2.6953,942
$2.75-0.18-6.1%$2.958$2.958$2.6666,024
$2.93-0.40-12.0%$3.10$3.21$2.65112,300
$3.33+0.22+7.1%$2.94$3.443$2.93182,700
$3.11+0.15+5.1%$3.00$3.14$2.88495,400
$2.96+0.31+11.7%$2.65$3.34$2.65586,700
$2.65-0.35-11.7%$3.06$3.11$2.5889,600
$3.00-0.34-10.2%$3.40$3.44$2.625,655
$3.34-0.96-22.3%$3.34$3.80$3.167,796
$4.30-0.10-2.3%$4.56$4.60$4.30904
$4.40-0.44-9.1%$4.68$4.88$4.281,683
$4.84+0.40+9.0%$4.48$5.04$4.343,175
$4.44-0.16-3.5%$4.42$4.58$4.102,246
$4.60-0.26-5.3%$4.58$4.60$3.723,916
$4.86+0.14+3.0%$4.70$4.96$4.244,346
$4.72-1.32-21.9%$5.78$5.98$4.6012,127
$6.04-0.72-10.7%$6.18$6.60$5.626,177
$6.76-1.84-21.4%$8.02$8.04$6.6217,385
$8.60-5.40-38.6%$9.42$9.42$7.60296,166
$14.00+6.04+75.9%$8.20$31.20$8.00444,899
$7.96-0.44-5.2%$8.64$8.68$7.1211,312
$8.40-4.94-37.0%$9.70$10.00$8.245,326
$13.34-0.42-3.1%$14.20$14.98$13.34374
$13.76-1.70-11.0%$15.60$15.60$13.44330
$15.46-0.28-1.8%$16.10$16.68$15.46118
$15.74-0.62-3.8%$16.20$16.24$15.5695
$16.36-0.50-3.0%$16.84$17.00$16.3494
$16.86+0.86+5.4%$16.76$17.20$16.02329
$16.00-1.52-8.7%$17.36$17.60$15.56476
$17.52-0.60-3.3%$18.00$18.56$17.40237
$18.12-0.06-0.3%$18.54$19.20$17.201,000
$18.18+0.18+1.0%$17.80$19.40$17.20548
$18.00+1.18+7.0%$16.40$18.00$16.40394
$16.82-3.78-18.3%$20.20$20.20$16.82889
$20.600.000.0%$20.44$21.16$20.30312
$20.60-0.80-3.7%$21.36$21.36$20.50215
$21.40+0.20+0.9%$21.00$21.60$21.00157
$21.20-0.40-1.9%$22.00$22.30$21.00242
$21.60-0.80-3.6%$22.80$22.80$21.60360
$22.40-0.60-2.6%$22.80$23.00$22.20218
$23.00+0.20+0.9%$23.60$24.70$22.70720
$22.80+0.60+2.7%$22.80$22.80$22.20203
$22.20-1.20-5.1%$23.36$23.40$22.20317
$23.40+0.80+3.5%$22.80$23.80$22.40323
$22.60+0.20+0.9%$22.40$23.00$22.20256
$22.40-0.60-2.6%$22.80$24.60$22.10907
$23.00-2.40-9.4%$25.60$25.60$22.801,115
$25.40+0.60+2.4%$25.00$26.00$23.602,548
$24.80+2.00+8.8%$26.00$26.20$20.2023,406
$22.80-0.40-1.7%$23.00$23.32$22.42131
$23.200.000.0%$23.40$23.40$22.40210
$23.200.000.0%$23.00$23.40$22.80247
$23.20-0.20-0.9%$23.20$23.20$22.10342

Splits

4 splits since 2024 · NASDAQ:SBFM · every price before a split is adjusted for it

DayRatioWhat
1-for-20Consolidation
1-for-10Consolidation
1-for-20Consolidation
1-for-100Consolidation
Ticker
NASDAQ:SBFM
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Sunshine Biopharma Inc. news

Sunshine Biopharma Inc. on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
20 in the last 12 months · 123 in all · newest Oct 22, 2026 · oldest 2019
Decks
1 deck · latest Feb 8, 2022

Where Sunshine Biopharma Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:SBFM · Home listing · This pageNASDAQUnited StatesUSD
BOATS:SBFMBOATSUnited StatesUSD

Valuation

EV/sales −0.3× against a median of 2.3×: 2nd lowest of 11 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$12.15M USD
P/E
Loss
EV/sales
−0.3×
EV/EBITDA
Negative EBITDA
Price/book
0.1×
Gross margin
30.4%
Operating margin
−17.2%
Net margin
−17.4%
Debt to equity
0.0×
Beta vs S&P 500
0.95

Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Sunshine Biopharma Inc. · NASDAQ:SBFMUS$1.84M−US$12.15Mn/a−0.3×n/a0.1×−17.4%0.0×0.95
Mangalam Drugs & Organics Ltd. · NSE:MANGALAMUS$4.71MUS$4.71Mn/a0.2×n/a0.4×−16.5%0.0×n/a
Vivimed Labs Limited · NSE:VIVIMEDLABUS$4.49MUS$46.53Mn/a6.2×n/an/a−252.1%n/an/a
Acrux Limited · ASX:ACRUS$4.05MUS$4.59Mn/a1.5×n/a4.2×−13.0%1.7×n/a
Scilex Holding Company · NASDAQ:SCLXUS$3.98MUS$98.96Mn/a3.1×n/an/an/an/a1.46
Scienture Holdings, Inc. · NASDAQ:SCNXUS$3.74MUS$8.36Mn/a5.6×n/a0.1×n/a0.2×1.74
Sanai Health Industry Group Company Limited · HKEX:1889US$2.42M−US$44.61Mn/a−3.5×n/a0.1×−25.7%0.0×n/a
Lasa Supergenerics Ltd. · NSE:LASAUS$2.17MUS$2.17Mn/a3.2×n/a0.4×−260.4%0.0×n/a
Ortin Global Ltd · NSE:ORTINGLOBEUS$1.09MUS$1.09Mn/a131×n/a8.1×n/a0.0×n/a
Rafarma Pharmaceuticals, Inc. (wy) · OTC:RAFAUS$877,670US$839,6702.5×0.1×n/a0.1×3.8%0.0×0.68
Evofem Biosciences, Inc. · OTC:EVFMUS$834,940US$517,940n/a0.0×n/an/a−71.7%n/a-0.14
Median of the othersUS$3.08MUS$3.38M2.5×2.3×0.4×−25.7%0.0×1.07

Forecasts

1 strong buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
1120.00 USD · Analysts' mean
EPS, year to Dec 2026
-39.00 · 1 analyst
Revenue, year to Dec 2026
36.75M · 1 analyst

Team and board

Officers

OfficerRole
Steve SlilatyChief Executive Officer
Camille SebaalyChief Financial Officer
Malek ChamounChief Development Officer
Michel RoyCHIEF COMMERCIAL OFFICER

Board

DirectorRole
Steve SlilatyChief Executive Officer
Andrew Kellerdirector
Camille SebaalyChief Financial Officer
David Natandirector
Rabi Kiderchahdirector

Events

QuarterResultsShare move
Q3 2026Nov 12, 2026 · After close−4.9%
Q2 2026Aug 13, 2026 · After close−4.2%
Q1 2026May 13, 2026 · After close−28.9%
Q4 2025Feb 25, 2026+5.1%
Q3 2025Nov 13, 2025 · After close−2.4%
Q2 2025Aug 12, 2025 · After close+5.6%
Q1 2025May 15, 2025+7.9%
Q3 2024Nov 5, 2024 · After close−6.3%
Q2 2024Aug 16, 2024 · After close+5.8%
Q1 2024May 20, 2024 · After close−17.8%
All 20 quarters
QuarterResultsShare move
Q4 2023Mar 28, 2024 · After close+75.4%
Q3 2023Nov 13, 2023 · Before open−12.1%
Q2 2023Aug 10, 2023 · After close0.0%
Q1 2023May 11, 2023 · Before open+69.8%
Q3 2022Nov 7, 2022−8.2%
Q2 2022Aug 4, 2022 · After close+11.4%
Q1 2022May 6, 2022−22.8%
Q4 2021Mar 21, 20220.0%
Quarter to Sep 30, 2021Nov 9, 2021
Quarter to Jun 30, 2021Aug 9, 2021

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (February 2022)Investor deck15 slidesFeb 8, 2022

Open Decks

Financings

RaiseDate
Public offering of common Units (or Pre-Funded Units)
Closed: US$6M raised · US$0.55 a unit · Warrants at US$0.66 for 60 months · Aegis Capital Corp.
Dealers: Aegis Capital Corp. (lead)
Use of proceeds: General corporate purposes and working capital
Oct 9, 2026
Registered direct offering of shares of Common Stock and pre-funded warrants
Closed: US$2.46M raised · US$2.07 a share · Aegis Capital Corp.
Dealers: Aegis Capital Corp. (lead)
Use of proceeds: General corporate purposes and working capital
Apr 3, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue36.3M34.9M24.1M4.35M228.4K71.4K21.1K000
Cost of revenue24.1M24.2M15.8M2.65M117.8K25.8K11.1K0060.7K
Gross profit12.3M10.7M8.34M1.70M110.6K45.6K10.1K00-60.7K
Research and development604.3K933.9K1.86M811.9K672.2K1.73K15.2K12.8K032.8K
Selling, general and administrative18.5M14.0M10.1M8.90M650.5K606.6K622.7K1.21M850.6K899.6K
Operating income-6.23M-5.81M-4.79M-27.0M-2.44M-576.9K-641.6K-1.16M-857.2K-993.1K
Depreciation and amortization332.1K223.5K149.1K25.2K12.7K14.1K13.8K49.4K6.63K60.7K
EBITDA-5.89M-5.59M-4.64M-27.0M-2.43M-562.8K-627.9K-1.11M-850.6K-932.4K
Interest expense08.77K137.3K39.4K328.8K168.1K115.9K143.5K104.8K34.7K
Income before tax-5.95M-5.37M-4.11M-26.5M-12.4M-2.78M-1.08M-2.14M-1.04M-3.50M
Income tax21.6K-234.9K395.2K233.3K00383.4K-41.5K1.29K2.47M
Net income-5.98M-5.13M-4.51M-26.7M-12.4M-2.78M-1.66M-2.16M-1.04M-3.50M
Earnings per share, basic-1.44-7.32-351.36-1.76-4.76-2.73-0.15-0.71-0.02-0.01
Earnings per share, diluted-7.32-351.36-1.76-4.76

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents9.12M9.69M16.3M21.8M2.05M989.9K40.5K110.5K107.5K57.5K
Short-term investments7.59K7.59K7.59K
Receivables3.46M3.87M2.55M1.91M7.80K1.92K43000
Inventory13.5M11.3M5.73M3.29M105.7K23.8K15.9K0-9.67K
Current assets26.9M26.0M24.9M27.3M2.20M1.03M65.7K1.10M117.2K58.5K
Property, plant and equipment557.4K546.1K365.9K394.2K7.06K19.5K32.5K45.1K60.0K5.94K
Goodwill0000665.7K665.7K0
Total assets30.1M30.6M27.3M29.2M2.20M1.05M98.1K1.15M257.5K64.4K
Accounts payable5.66M5.54M2.59M2.80M42.9K62.9K96.9K115.8K19.3K28.1K
Current liabilities6.44M6.31M5.55M6.93M91.2K1.05M833.5K912.5K751.1K274.1K
Long-term debt1.90M949.0K289.8K79.7K
Total debt812.4K952.5K657.7K765.3K1.90M949.0K715.6K952.6K802.3K237.0K
Total liabilities7.04M7.06M6.14M7.62M1.99M2.00M833.5K1.20M830.8K274.1K
Shareholders' equity23.0M23.5M21.2M21.6M211.7K-954.8K-735.4K-55.8K-573.4K-209.7K
Shares outstanding24.5K2.58M14.0K22.6M2.59M1.73M35.3M4.28M45.9M769.4M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-5.33M-12.5M-8.78M-5.25M-1.83M-657.3K-495.8K-512.8K-543.5K-314.2K
Capital spending-174.5K-1.66M-82.3K-194.0K0-1.19K-860-18.9K-3.72K-3.44K
Free cash flow-5.51M-14.2M-8.86M-5.44M-1.83M-658.5K-496.7K-531.7K-547.2K-317.6K
Cash from investing-836.3K-1.98M-656.1K-14.6M0-1.19K-15.3K-13.9K-84.0K-3.44K
Cash from financing4.75M8.94M3.43M39.5M2.90M1.61M442.3K527.6K670.7K324.6K
Dividends paid000
Share buybacks0-3.14M-541.1K-99.0K063.9K104.1K
Change in cash-1.42M-5.56M-6.01M19.6M1.08M949.8K-68.8K92643.2K7.00K

Open Financials

Filings

FilingDateTypeFiled with
S-1 · Registration statementNov 18, 2026Offer documentSEC
DEFA14A · Additional proxy materialNov 13, 2026Meeting noticeSEC
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
DEF 14A · Proxy statementNov 12, 2026Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 10, 2026Big-stake noticeSEC
DEF 14COct 27, 2026Meeting noticeSEC
PRE 14COct 14, 2026Meeting noticeSEC
8-K · Current reportOct 14, 2026Meeting outcomeSEC
SCHEDULE 13G · Big-stake noticeOct 14, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeOct 13, 2026Big-stake noticeSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportOct 9, 2026Material contractSEC
424B4 · ProspectusOct 9, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveOct 8, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 5, 2026Big-stake noticeSEC
S-1 · Registration statementOct 2, 2026Offer documentSEC
DEF 14CSep 28, 2026Meeting noticeSEC
DRS · Draft registration statementSep 24, 2026Offer documentSEC
PRE 14CSep 16, 2026Meeting noticeSEC
8-K · Current reportSep 16, 2026Meeting outcomeSEC
8-K · Current reportSep 11, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveSep 9, 2026Other filingsSEC
424B3 · ProspectusSep 8, 2026Offer documentSEC
S-1 · Registration statementAug 28, 2026Offer documentSEC
8-K · Current reportAug 28, 2026Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2026Big-stake noticeSEC
4 · Change in ownershipAug 11, 2026Insider tradeSEC
8-K · Current reportAug 3, 2026Current reportSEC
424B5 · ProspectusJul 20, 2026Offer documentSEC
8-K · Current reportJul 20, 2026Material contractSEC
8-K · Current reportJul 10, 2026Material contractSEC
SCHEDULE 13G · Big-stake noticeJul 8, 2026Big-stake noticeSEC
DEF 14CJun 8, 2026Meeting noticeSEC
PRE 14CMay 29, 2026Meeting noticeSEC
8-K · Current reportMay 29, 2026Meeting outcomeSEC
SCHEDULE 13G · Big-stake noticeMay 22, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 21, 2026Big-stake noticeSEC
8-K · Current reportMay 19, 2026Material contractSEC
424B4 · ProspectusMay 19, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveMay 19, 2026Other filingsSEC
CORRESP · Letter to the SECMay 18, 2026Other filingsSEC
CORRESP · Letter to the SECMay 18, 2026Other filingsSEC
CORRESP · Letter to the SECMay 14, 2026Other filingsSEC
CORRESP · Letter to the SECMay 14, 2026Other filingsSEC
10-Q · Quarterly reportMay 13, 2026Quarterly reportSEC
S-1 · Registration statementMay 12, 2026Offer documentSEC
UPLOAD · Letter from the SECMay 4, 2026Other filingsSEC
DRSLTR · Letter to the SEC with a draftApr 28, 2026Other filingsSEC
DRS · Draft registration statementApr 28, 2026Offer documentSEC
4 · Change in ownershipApr 14, 2026Insider tradeSEC
8-K · Current reportApr 9, 2026ResultsSEC
10-K · Annual reportApr 3, 2026Annual reportSEC
NT 10-K · Late filing noticeMar 31, 2026Explanation requestSEC
8-K · Current reportMar 9, 2026Current reportSEC
DEF 14CMar 2, 2026Meeting noticeSEC
8-K · Current reportFeb 20, 2026Meeting outcomeSEC
PRE 14CFeb 20, 2026Meeting noticeSEC
8-K · Current reportFeb 5, 2026Management or board changeSEC
8-K · Current reportDec 12, 2025Meeting outcomeSEC
10-Q · Quarterly reportNov 13, 2025Quarterly reportSEC
DEFA14A · Additional proxy materialOct 23, 2025Meeting noticeSEC
DEF 14A · Proxy statementOct 23, 2025Meeting noticeSEC
8-K · Current reportSep 30, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveAug 13, 2025Other filingsSEC
10-Q · Quarterly reportAug 12, 2025Quarterly reportSEC
424B3 · ProspectusAug 12, 2025Offer documentSEC
RW · Request to withdraw a registrationAug 12, 2025Other filingsSEC
UPLOAD · Letter from the SECAug 11, 2025Other filingsSEC
CORRESP · Letter to the SECAug 11, 2025Other filingsSEC
S-1 · Registration statementAug 4, 2025Offer documentSEC
POS AM · Amendment to an effective registrationJul 25, 2025Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedJun 12, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 23, 2025Big-stake noticeSEC
8-K · Current reportMay 19, 2025ResultsSEC
10-Q · Quarterly reportMay 15, 2025Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeApr 11, 2025Big-stake noticeSEC
8-K · Current reportApr 3, 2025Material contractSEC
424B5 · ProspectusApr 3, 2025Offer documentSEC
8-K · Current reportApr 2, 2025ResultsSEC
10-K · Annual reportApr 1, 2025Annual reportSEC
NT 10-K · Late filing noticeMar 31, 2025Explanation requestSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
3 · Initial statement of ownershipJan 21, 2025Insider tradeSEC
EFFECT · Notice that a registration is effectiveJan 16, 2025Other filingsSEC
8-K · Current reportJan 15, 2025Management or board changeSEC
CORRESP · Letter to the SECJan 13, 2025Other filingsSEC
UPLOAD · Letter from the SECJan 13, 2025Other filingsSEC
S-3 · Registration statementJan 6, 2025Offer documentSEC
8-K · Current reportDec 10, 2024Meeting outcomeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
424B4 · ProspectusNov 12, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveNov 12, 2024Other filingsSEC
8-K · Current reportNov 7, 2024ResultsSEC
POS AM · Amendment to an effective registrationNov 6, 2024Offer documentSEC
10-Q · Quarterly reportNov 5, 2024Quarterly reportSEC
8-K · Current reportOct 23, 2024Management or board changeSEC
DEF 14A · Proxy statementOct 17, 2024Meeting noticeSEC
8-K · Current reportSep 10, 2024Current reportSEC
10-Q/A · Quarterly report, amendedAug 20, 2024Quarterly reportSEC
8-K · Current reportAug 19, 2024ResultsSEC
10-Q · Quarterly reportAug 16, 2024Quarterly reportSEC
NT 10-Q · Late filing noticeAug 14, 2024Explanation requestSEC
8-K · Current reportAug 12, 2024Current reportSEC
DEF 14CJul 11, 2024Meeting noticeSEC
8-K · Current reportJul 2, 2024Meeting outcomeSEC
PRE 14CJul 1, 2024Meeting noticeSEC
8-K · Current reportJul 1, 2024Current reportSEC
8-K · Current reportJun 11, 2024Current reportSEC
8-K · Current reportJun 7, 2024Current reportSEC
8-K · Current reportMay 22, 2024ResultsSEC
10-Q · Quarterly reportMay 20, 2024Quarterly reportSEC
NT 10-Q · Late filing noticeMay 15, 2024Explanation requestSEC
8-K · Current reportMay 8, 2024Current reportSEC
8-K · Current reportMay 6, 2024Current reportSEC
8-K · Current reportApr 23, 2024Current reportSEC
8-K · Current reportApr 1, 2024ResultsSEC
10-K · Annual reportMar 28, 2024Annual reportSEC
DEF 14CMar 15, 2024Meeting noticeSEC
8-K · Current reportMar 6, 2024Material contractSEC
PRE 14CMar 5, 2024Meeting noticeSEC
4 · Change in ownershipMar 5, 2024Insider tradeSEC
DEF 14CMar 4, 2024Meeting noticeSEC
8-K · Current reportMar 1, 2024Current reportSEC
SC 13G · Big-stake noticeFeb 23, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 21, 2024Big-stake noticeSEC
PRE 14CFeb 21, 2024Meeting noticeSEC
8-K · Current reportFeb 16, 2024Meeting outcomeSEC
8-K · Current reportFeb 15, 2024Material contractSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
424B4 · ProspectusFeb 14, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveFeb 13, 2024Other filingsSEC
4 · Change in ownershipFeb 12, 2024Insider tradeSEC
8-K · Current reportFeb 12, 2024Material contractSEC
CORRESP · Letter to the SECFeb 9, 2024Other filingsSEC
CORRESP · Letter to the SECFeb 9, 2024Other filingsSEC
S-1/A · Registration statement, amendedFeb 9, 2024Offer documentSEC
3 · Initial statement of ownershipFeb 9, 2024Insider tradeSEC
UPLOAD · Letter from the SECFeb 6, 2024Other filingsSEC
S-1 · Registration statementFeb 1, 2024Offer documentSEC
8-K · Current reportJan 30, 2024Management or board changeSEC
S-8 · Registration statement for employee plansJan 8, 2024Offer documentSEC
8-K · Current reportDec 7, 2023Meeting outcomeSEC
8-K · Current reportNov 13, 2023ResultsSEC
10-Q · Quarterly reportNov 13, 2023Quarterly reportSEC
8-K · Current reportNov 2, 2023Current reportSEC
8-K · Current reportOct 20, 2023Material contractSEC
DEFA14A · Additional proxy materialOct 19, 2023Meeting noticeSEC
DEF 14A · Proxy statementOct 18, 2023Meeting noticeSEC
8-K · Current reportOct 13, 2023Meeting outcomeSEC
8-K · Current reportSep 21, 2023Current reportSEC
DEF 14A · Proxy statementSep 5, 2023Meeting noticeSEC
UPLOAD · Letter from the SECAug 29, 2023Other filingsSEC
PRE 14A · Preliminary proxy statementAug 25, 2023Meeting noticeSEC
8-K · Current reportAug 11, 2023ResultsSEC
10-Q · Quarterly reportAug 10, 2023Quarterly reportSEC
CORRESP · Letter to the SECAug 8, 2023Other filingsSEC
UPLOAD · Letter from the SECJul 25, 2023Other filingsSEC
EFFECT · Notice that a registration is effectiveJun 6, 2023Other filingsSEC
424B3 · ProspectusJun 5, 2023Offer documentSEC
CORRESP · Letter to the SECJun 1, 2023Other filingsSEC
UPLOAD · Letter from the SECJun 1, 2023Other filingsSEC
S-3 · Registration statementMay 25, 2023Offer documentSEC
DMay 17, 2023Other filingsSEC
8-K · Current reportMay 16, 2023Material contractSEC
8-K · Current reportMay 11, 2023ResultsSEC
10-Q · Quarterly reportMay 10, 2023Quarterly reportSEC
PRE 14A · Preliminary proxy statementMay 2, 2023Meeting noticeSEC
8-K · Current reportApr 19, 2023Current reportSEC
10-K · Annual reportApr 3, 2023Annual reportSEC
NT 10-K · Late filing noticeMar 31, 2023Explanation requestSEC
8-K · Current reportMar 24, 2023Current reportSEC
8-K · Current reportFeb 28, 2023Material contractSEC
8-K · Current reportFeb 13, 2023Current reportSEC
8-K · Current reportFeb 10, 2023Material contractSEC
8-K/A · Current report, amendedDec 12, 2022Current reportSEC
8-K · Current reportDec 9, 2022Current reportSEC
4 · Change in ownershipDec 2, 2022Insider tradeSEC
10-Q · Quarterly reportNov 7, 2022Quarterly reportSEC
SC 13G · Big-stake noticeNov 2, 2022Big-stake noticeSEC
3 · Initial statement of ownershipOct 26, 2022Insider tradeSEC
8-K · Current reportOct 20, 2022Acquisition or disposalSEC
10-Q · Quarterly reportAug 3, 2022Quarterly reportSEC
4 · Change in ownershipJun 6, 2022Insider tradeSEC
EFFECT · Notice that a registration is effectiveMay 23, 2022Other filingsSEC
424B3 · ProspectusMay 20, 2022Offer documentSEC
CORRESP · Letter to the SECMay 18, 2022Other filingsSEC
UPLOAD · Letter from the SECMay 18, 2022Other filingsSEC
S-3 · Registration statementMay 10, 2022Offer documentSEC
10-Q · Quarterly reportMay 6, 2022Quarterly reportSEC
DApr 29, 2022Other filingsSEC
8-K · Current reportApr 28, 2022Material contractSEC
EFFECT · Notice that a registration is effectiveApr 11, 2022Other filingsSEC
8-K · Current reportApr 8, 2022Management or board changeSEC
424B3 · ProspectusApr 8, 2022Offer documentSEC
CORRESP · Letter to the SECApr 7, 2022Other filingsSEC
UPLOAD · Letter from the SECApr 7, 2022Other filingsSEC
S-3 · Registration statementMar 30, 2022Offer documentSEC
8-K · Current reportMar 24, 2022Current reportSEC

This page holds 200 of 433 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Sunshine Biopharma Inc.’s releases · as of Oct 9, 2026

Common shares
823,772
Fully diluted
823,772

Fully diluted

LineShares
Common shares823,772

Warrants and options

Lot
Warrants · US$0.66 · expire about Oct 2031

Share count over time

CountShares
Nov 22, 2026823,772
Oct 22, 2026
May 28, 2026

Open Cap table

Shareholders

StakeStakeSharesDateFiling
Mitchell P. Kopin9.99%506KMay 19, 2025Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
David Natan
Other companies: Aterian, Inc. (Director · Since at least Jul 17, 2026); Quantum Cyber N.V. (Board Member · Since at least Apr 22, 2026); Indaptus Therapeutics, Inc. (Director · Since at least Jan 7, 2026); Sow Good Inc. (Director · Since at least Dec 31, 2025); FiEE, Inc (Director · Since at least Nov 8, 2023); The Crypto Company (Chief Financial Officer · Mar 12, 2025 – Mar 12, 2025 · Past); Bio Green Med Solution, Inc. (Director · Jan 2, 2025 – Feb 26, 2025 · Past); CapForce Inc. (Director · Mar 25, 2024 – Apr 11, 2024 · Past); Vivakor, Inc. (Director · Dec 15, 2022 – Dec 15, 2022 · Past); Titan Pharmaceuticals Inc (Director · Aug 15, 2022 – Oct 25, 2023 · Past); NetBrands Corp. (Director · Feb 24, 2021 – Apr 25, 2022 · Past); PharmaNet Development Group Inc (Former EVP · Aug 3, 2007 – Dec 10, 2007 · Past)
director · Since at least Feb 10, 2022
Andrew Kellerdirector · Since at least Nov 5, 2026
Camille SebaalyChief Financial Officer · Since at least Aug 7, 2026
James Daniel KishDirector · Oct 31, 2021 – Oct 31, 2021 · Past
Malek ChamounChief Development Officer · Since at least Nov 5, 2026
Michel RoyCHIEF COMMERCIAL OFFICER · Since at least Jan 15, 2025
Rabi Kiderchahdirector · Since at least Nov 5, 2026
Steve SlilatyChief Executive Officer · Since at least Sep 24, 2026

Open People

Log in to ask 6ix AI your own questions about Sunshine Biopharma Inc.